ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
If approved, cabotegravir would be the first, long-acting therapy for HIV PrEP.
Communiqués
Résultats de l’étude de phase II pour la recherche de dose pour l’islatravir en mensuel en PrEP
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021. Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent.
Autorisation de mise sur le marché en Europe de Rukobia® (fostemsavir)
ViiV Healthcare receives Marketing Authorisation for Rukobia® (fostemsavir), a first-in-class attachmentinhibitor in combination with other antiretrovirals for the treatment of adults with multi drug-resistant HIV. Fostemsavir addresses a critical need in HIV care for those with little to no treatment options left who are at risk of further disease progression, or complications from HIV.
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option to Help Address the HIV Epidemic with Focus on Women in Sub-Saharan Africa.
ViiV Healthcare lance la campagne «Moins de VIH, plus de VIE» dans l’objectif d’améliorer la prise en charge globale des personnes vivant avec le VIH et donner priorité à leur qualité de vie.
Le programme de cette campagne s’adresse aux patients, aux professionnels de santé et aux associations de patients et poursuit l’engagement de ViiV Healthcare au-delà du médicament pour accompagner et aider les PVVIH dans leur quotidien.